[Creutzfeldt Jakob Disease[/diseases/[creutzfeldt-jakob-disease[/diseases/[creutzfeldt-jakob-disease[/diseases/[creutzfeldt-jakob-disease[/diseases/[creutzfeldt-jakob-disease--TEMP--/diseases)--FIX-- (CJD) is a progressive neurodegenerative disorder characterized affecting millions worldwide. This page provides comprehensive information about the disease, including its mechanisms, symptoms, diagnosis, and treatment approaches.
Creutzfeldt-Jakob Disease (CJD) is a rare, fatal, and rapidly progressive neurodegenerative disorder classified as a transmissible spongiform encephalopathy (TSE) or [prion disease[/diseases/[prion-disease[/diseases/[prion-disease[/diseases/[prion-disease[/diseases/[prion-disease--TEMP--/diseases)--FIX--. It is characterized by the accumulation of abnormal [prion protein[/proteins/[prion-protein[/proteins/[prion-protein[/proteins/[prion-protein[/proteins/[prion-protein--TEMP--/proteins)--FIX-- (PrP^Sc) in the brain, leading to spongiform degeneration, [neuronal] loss, and [astrocytic] gliosis. CJD is the most common human Prion Disease, with an annual incidence of approximately 1-2 cases per million people worldwide (~350 cases annually in the United States) (Geschwind, 2015).
The disease was first described independently by German neurologists Hans Gerhard Creutzfeldt in 1920 and Alfons Maria Jakob in 1921. [The connection to prions was not established until Stanley Prusiner's groundbreaking work in the 1980s, for which he received the Nobel Prize in Physiology or Medicine in 1997 (Prusiner, 1982)). The identification of variant CJD (vCJD) in 1996 provided the first evidence that bovine spongiform encephalopathy (BSE) could cross species barriers to infect humans (Will et al., 1996).
Sporadic CJD accounts for approximately 85-90% of all cases and occurs spontaneously without known genetic or [environmental risk factors[/mechanisms/[environmental-risk-factors[/mechanisms/[environmental-risk-factors[/mechanisms/[environmental-risk-factors[/mechanisms/[environmental-risk-factors--TEMP--/mechanisms)--FIX-- (Parchi et al., 1999):
- Incidence: ~1-2 per million per year
- Mean age of onset: 60-65 years
- Median survival: 4-6 months (90% die within 1 year)
- Cause: Unknown; possibly spontaneous misfolding of PrP^C or somatic PRNP mutations
sCJD is subtyped by the PRNP codon 129 genotype (MM, MV, or VV) and the PrP^Sc type (type 1 or type 2), creating six molecular subtypes with distinct clinical presentations:
| Subtype |
Frequency |
Clinical Features |
Duration |
| MM1/MV1 |
~70% |
Classic: rapid dementia, myoclonus, EEG changes |
3-4 months |
| VV2 |
~16% |
Cerebellar ataxia, later dementia |
6-7 months |
| MV2 |
~9% |
Ataxia, dementia, longer course |
17-18 months |
| MM2-cortical |
~2% |
Progressive dementia, longer course |
15-16 months |
| MM2-thalamic |
~2% |
Insomnia, dysautonomia (sporadic fatal insomnia) |
16 months |
| VV1 |
~1% |
Early onset, progressive dementia |
15-21 months |
Familial CJD comprises about 10-15% of cases and follows autosomal dominant inheritance with PRNP gene mutations on chromosome 20p13 (Windl et al., 1999):
- E200K mutation: Most common worldwide; similar clinical presentation to sCJD but with younger onset
- D178N with valine at codon 129: Produces familial CJD phenotype
- D178N with methionine at codon 129: Produces fatal familial insomnia (FFI) phenotype
- V210I, R208H, E196K: Other pathogenic mutations with varying penetrance
Over 50 pathogenic PRNP mutations have been identified. Genetic counseling is recommended for all families with inherited Prion Disease.
Iatrogenic CJD results from accidental transmission of prions through medical procedures (Brown et al., 2000):
- Dura mater grafts (Lyodura): Largest source; primarily reported from Japan
- Pituitary-derived growth hormone: Over 200 cases worldwide before recombinant hormone became available
- Corneal transplants: Rare cases documented
- Contaminated neurosurgical instruments: Historical cases; standard autoclaving is insufficient for prion inactivation
- Blood transfusion: Four confirmed cases of vCJD transmission in the UK
Variant CJD was first identified in 1996 in the UK and is causally linked to bovine spongiform encephalopathy (BSE) (Will et al., 1996):
- Median age of onset: 28 years (significantly younger than sCJD)
- Duration: 12-14 months
- Cumulative cases: ~230 worldwide (majority in UK)
- Clinical features: Prominent early psychiatric symptoms (depression, anxiety, behavioral changes) and painful sensory symptoms preceding dementia and ataxia
- Genetic susceptibility: All definite clinical cases to date have been methionine homozygous (MM) at codon 129
The central event in CJD is the conformational conversion of normal PrP^C into PrP^Sc. This post-translational process transforms the alpha-helix-rich structure of PrP^C into a beta-sheet-dominated conformation that is insoluble, protease-resistant, and self-propagating (Caughey & Lansbury, 2003).
Multiple interconnected pathways contribute to neurodegeneration:
- [unfolded protein response[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress--TEMP--/mechanisms)--FIX-- ([UPR[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress--TEMP--/mechanisms)--FIX-- activation: PrP^Sc accumulation in the endoplasmic reticulum triggers chronic [UPR[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress--TEMP--/mechanisms)--FIX-- activation, leading to sustained translational repression via PERK-eIF2alpha signaling and eventual [neuronal] death
- [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--: Increased [reactive oxygen species[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- production, [mitochondrial dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction--TEMP--/mechanisms)--FIX--, and depleted antioxidant defenses
- Synaptic dysfunction: Early and progressive synaptic loss affecting neurotransmission, particularly in the [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, and [cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX--
- **Microglial (Budka et al., 1995)
- Rapidly progressive dementia: Global cognitive decline progressing over weeks to months, often beginning with memory difficulties and progressing to akinetic mutism
- Myoclonus: Involuntary, stimulus-sensitive jerking movements; present in ~80% of sCJD
- Cerebellar ataxia: Gait instability, incoordination, and dysmetria
- Cortical blindness (Heidenhain variant): Visual disturbances as the presenting feature
- Pyramidal signs: Spasticity, hyperreflexia, Babinski sign
- Extrapyramidal signs: Parkinsonism, [dystonia[/diseases/[dystonia[/diseases/[dystonia[/diseases/[dystonia[/diseases/[dystonia--TEMP--/diseases)--FIX--, choreoathetosis
- Speech dysfunction: Dysarthria progressing to mutism
- Seizures: Focal or generalized, in ~10-15% of cases
¶ Psychiatric and Behavioral Symptoms
Depression, anxiety, apathy, agitation, and psychosis may occur, particularly early in vCJD. Initial psychiatric presentation is common in vCJD and younger patients, often delaying the correct diagnosis by weeks to months.
The updated criteria (Zerr et al., 2009) classify sCJD as:
- Definite: Neuropathological confirmation with PrP^Sc detection by immunohistochemistry or Western blot
- Probable: Progressive dementia + at least 2 of 4 clinical features (myoclonus, visual/cerebellar, pyramidal/extrapyramidal, akinetic mutism) + supportive investigation (EEG, MRI, or CSF)
- Possible: Progressive dementia + clinical features but lacking supportive investigation findings
-
MRI Brain (most useful imaging modality):
- Diffusion-weighted imaging (DWI): Cortical ribboning and/or caudate/putamen hyperintensity; sensitivity ~92%, specificity ~95%
- FLAIR: May show similar patterns but less sensitive than DWI
- Cortical atrophy: Progressive with disease
-
Real-Time Quaking-Induced Conversion (RT-QuIC):
- Ultrasensitive assay detecting PrP^Sc seeding activity in CSF
- Sensitivity ~92%, specificity ~100% for sCJD
- Can be performed on nasal brushings (sensitivity ~97%) and skin biopsies
- Has transformed pre-mortem diagnosis (McGuire et al., 2012)
-
CSF Biomarkers:
- 14-3-3 protein: Sensitivity ~85-95%, specificity ~75-85%; reflects rapid neuronal destruction
- Total tau]: Markedly elevated (>1,150 pg/mL); correlates with disease progression
- [Neurofilament light chain[/proteins/[nfl-protein[/proteins/[nfl-protein[/proteins/[nfl-protein[/proteins/[nfl-protein--TEMP--/proteins)--FIX-- (NfL): Elevated; reflects axonal damage
- RT-QuIC: See above
-
EEG: Periodic sharp wave complexes (PSWC) in 60-80% of sCJD (mainly MM1/MV1 subtypes); typical 1-2 Hz generalized periodic discharges
-
PRNP Gene Sequencing: Essential for identifying familial forms; codon 129 genotyping provides subtype classification
-
Brain Biopsy/Autopsy: Gold standard; reserved for atypical cases. Immunohistochemistry for PrP^Sc provides definitive diagnosis.
There is no cure for CJD. All [treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/treatments are supportive and palliative:
- Myoclonus: Clonazepam (first-line), sodium valproate, levetiracetam
- Seizures: Standard antiepileptic medications
- Pain: Standard analgesic protocols; opioids for severe pain
- Psychiatric symptoms: Cautious use of antipsychotics and anxiolytics
- Dysphagia: Swallowing assessment; PEG tube consideration
- Physical therapy: Maintain mobility and comfort
- Palliative care: Early involvement of palliative care teams
- Family support: Genetic counseling for familial cases; psychological support
- Antisense oligonucleotides (ASOs): Targeting PRNP mRNA to reduce PrP^C expression; the most promising therapeutic strategy based on preclinical data showing up to 98% survival extension in mice (Raymond et al., 2019)
- [Immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy--TEMP--/treatments)--FIX--: Anti-PrP antibodies and vaccination approaches; limited by [blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- penetration
- Small molecule inhibitors:
- Efavirenz (anti-HIV drug): Extended survival in scrapie-infected mice via brain cholesterol regulation (JCI Insight, 2024)
- Anle138b: Oligomer modulator with preclinical efficacy
- Gene therapy: AAV-mediated delivery of anti-prion constructs and CRISPR-based PRNP silencing (preclinical)
Past [clinical trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/clinical-trials of quinacrine, pentosan polysulfate, and doxycycline have not demonstrated clear efficacy.
Conditions that may mimic CJD include:
- [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- (rapidly progressive variant)
- [Lewy body dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX-- (rapid cognitive decline with movement disorder)
- [frontotemporal dementia[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- (behavioral variant)
- Autoimmune encephalitis (anti-[NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor] receptor] receptor, anti-LGI1, anti-CASPR2)
- Paraneoplastic neurological syndromes
- CNS vasculitis
- Viral encephalitis (HSV, EBV)
- Hashimoto's encephalopathy (steroid-responsive encephalopathy)
- Non-convulsive status epilepticus
- Metabolic encephalopathies (hepatic, uremic)
Autoimmune encephalitis is an especially important differential diagnosis, as it is treatable and increasingly recognized.
| Feature |
sCJD |
fCJD |
iCJD |
vCJD |
| Frequency |
85-90% |
10-15% |
<1% |
<1% |
| Mean onset age |
60-65 yrs |
50-60 yrs |
Variable |
28 yrs |
| Median survival |
4-6 months |
Variable |
Variable |
12-14 months |
| Sex ratio (M:F) |
1.2:1 |
1:1 |
Variable |
~1:1 |
| Cause |
Spontaneous |
PRNP mutation |
Medical exposure |
BSE prions |
The PRNP gene polymorphisms profoundly influence disease susceptibility and phenotype:
- Codon 129 polymorphism: The most important genetic modifier. Homozygosity (MM or VV) increases risk for sCJD and vCJD. ~70% of sCJD patients are MM at codon 129 versus ~40% in the general European population.
- Pathogenic mutations: Over 50 mutations identified (E200K, D178N, V210I, P102L, etc.)
- Protective heterozygosity: MV heterozygosity at codon 129 appears protective against both sCJD and vCJD (Mead et al., 2003)
CJD is uniformly fatal:
- sCJD: ~90% of patients die within 1 year of symptom onset; median survival 4-6 months
- fCJD: Variable; some forms (E200K) similar to sCJD; others (P102L/GSS) may survive 2-10 years
- vCJD: Median survival 12-14 months
- Death typically results from pneumonia, other infections, or central respiratory failure in the terminal akinetic mutism stage
The study of Creutzfeldt Jakob Disease (Cjd) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Diseases Index[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases
- [Prion Diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases
- [Neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms
- [Dementia[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases
- [Geschwind MD. Prion [diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases/diseases]. Continuum. 2015;21(6):1612-1638. DOI
- [Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216(4542):136-144. DOI
- [Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob Disease in the UK. Lancet. 1996;347(9006):921-925. DOI
- [Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob Disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999;46(6):731-741. DOI
- [Brown P, Preece M, Brandel JP, et al. Iatrogenic Creutzfeldt-Jakob Disease at the millennium. Neurology. 2000;55(8):1075-1081. DOI
- [Windl O, Giese A, Schulz-Schaeffer W, et al. Molecular [genetics[/mechanisms/[genetics[/mechanisms/[genetics[/mechanisms/[genetics[/mechanisms/[genetics--TEMP--/mechanisms)--FIX-- of human prion diseases in Germany. Hum Genet. 1999;105(3):244-252. DOI
- [Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration. Annu Rev Neurosci. 2003;26:267-298. DOI
- [Budka H, Aguzzi A, Brown P, et al. Neuropathological diagnostic criteria for Creutzfeldt-Jakob Disease. Brain Pathol. 1995;5(4):459-466. DOI
- [Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob Disease. Brain. 2009;132(10):2659-2668. DOI
- [McGuire LI, Peden AH, Orru CD, et al. Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob Disease. Ann Neurol. 2012;72(2):278-285. DOI
- [Raymond GJ, Zhao HT, Race B, et al. Antisense oligonucleotides extend survival of prion-infected mice. JCI Insight. 2019;4(16):e131175. DOI
- [Mead S, Stumpf MP, Whitfield J, et al. Balancing selection at the prion protein gene consistent with prehistoric kuru-like epidemics. Science. 2003;300(5619):640-643. DOI
- [Bhatt D, et al. Treatment with efavirenz extends survival in a Creutzfeldt-Jakob Disease model. JCI Insight. 2024;9(22):e190296. DOI
- [Collins SJ, Lawson VA, Masters CL. Transmissible spongiform encephalopathies. Lancet. 2004;363(9402):51-61. DOI
- [Prusiner SB. Prions. Proc Natl Acad Sci USA. 1998;95(23):13363-13383. DOI
- National Prion Disease Pathology Surveillance Center. [Case Western Reserve University[/[neuroinflammation[/[neuroinflammation[/[neuroinflammation[/[neuroinflammation[/[neuroinflammation[/[neuroinflammation[/[neuroinflammation[/neuroinflammation] — Microglial activation in prion diseases